PRQR
ProQR Therapeutics BV
1.60$
+0.3%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -1,457.5% | -4,618.8% | -257.6% | -1,499.6% | – | -621.0% | -2,274.7% | -4,573.4% | -1,948.5% | -1,906.2% | 330.8% | -192.5% | -345.5% | |
| – | 15.0% | 40.3% | 5.1% | 54.6% | – | 20.1% | 106.2% | 228.9% | 174.5% | 70.1% | 38.6% | 14.6% | 17.7% | |
| – | 25.6% | 206.4% | 12.9% | 107.5% | – | 65.2% | 471.2% | 761.7% | 465.6% | 79.8% | 47.7% | 13.5% | 26.3% | |
| – | 42.5% | -1,132.9% | -66.8% | 96.6% | – | 123.8% | 455.6% | 222.0% | 620.6% | -13.5% | – | – | – | |
| – | 518.1% | 348.2% | 6.8% | 62.8% | – | 26.2% | 87.6% | -532.0% | 1,873.7% | -138.9% | 751.6% | -70.2% | -114.0% | |
| 0.0% | 85.6% | 393.9% | 14.1% | 111.3% | – | 6.3% | 30.0% | 89.8% | 36.3% | 19.7% | 21.0% | 7.5% | 6.7% | |
| – | -85.6% | -393.9% | -14.1% | -111.3% | – | -6.3% | -30.0% | -89.8% | -31.8% | -19.5% | 65.7% | -21.5% | -6.7% | |
| – | – | – | 0.0% | 0.0% | – | 0.0% | 0.0% | – | – | – | – | – | – | |
| – | 1,889.4% | 37,779.6% | 0.1% | 0.1% | – | 1,721.5% | 2,521.6% | – | – | – | – | – | – | |
| – | 2,078.8% | 521.7% | 23.7% | 15.6% | – | 28.3% | 75.3% | 1,337.7% | 2,010.3% | -1,253.4% | -40.4% | -8.4% | -12.5% | |
| 2,693.3% | 3,968.1% | 38,301.3% | 17.2% | 15.6% | – | 1,794.1% | 2,596.9% | 1,409.1% | 10,249.6% | -859.5% | -34.9% | 371.7% | -12.0% | |
| – | 2,425.0% | 34,698.7% | -190.0% | -1,562.9% | – | 1,163.3% | 329.5% | -3,509.4% | 8,366.0% | -2,580.7% | 370.7% | 161.2% | -373.0% | |
| – | -1,543.1% | -5,012.8% | -271.7% | -1,610.9% | – | -627.3% | -2,304.7% | -4,663.2% | -1,984.7% | -1,925.9% | 309.7% | -200.0% | -352.2% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.